▶ Watch & exploreScience foundations
Peptides: start with the building blocks
Learn how amino acids form peptides, why some act as signals and why the word “peptide” is not evidence of a shared health benefit.
NEW TO PEPTIDES? START HERE
Peptides are short chains of amino acids, the building blocks also used in proteins. Different peptides have different roles and evidence. Start with the basics, or explore familiar GLP names such as Ozempic and Reta below.
Peptide definition · NIH / NHGRI ↗YOUR FIRST GUIDE
Learn how amino acids form peptides, why some act as signals and why the word “peptide” is not evidence of a shared health benefit.
Watch & learn the basics
Peptide basics · Start hereRESEARCH LIBRARY
Browse by interest. Categories describe research topics, not promised benefits. Each guide keeps the study context, sources and evidence limits together.
8 of 8 published guides
EXPLORE THE TOPIC
Understand the building blocks, then learn how to read a study.
▶ Watch & exploreScience foundations
Learn how amino acids form peptides, why some act as signals and why the word “peptide” is not evidence of a shared health benefit.
Research overviewScience foundations
An illustrated guide to reading peptide studies: distinguish cell, animal and human evidence, interpret biomarkers, and check comparisons and limitations.
EXPLORE THE TOPIC
Connect familiar names with compound names, receptor targets and trial evidence.
KNOW A NAME LIKE OZEMPIC?
A brand name, a compound name and a receptor target describe different things. These examples help connect the terms.
Prescription brands
Ozempic · Wegovy
Receptor targets
GLP-1
Ozempic and Wegovy are brand names for medicines containing semaglutide. Semaglutide activates GLP-1 receptors; each medicine has its own approved uses and formulation.
NIH medicine-name reference ↗Prescription brands
Mounjaro · Zepbound
Receptor targets
GIP + GLP-1
Mounjaro and Zepbound contain tirzepatide. It activates two receptor types, GIP and GLP-1, and is a different compound from semaglutide.
NIH medicine-name reference ↗Investigational · Phase 3
Often called “Reta”
Receptor targets
GIP + GLP-1 + glucagon
Reta is a newer compound in weight-management research. It activates three receptor types and remains investigational, without FDA approval. More receptor targets do not establish that it is the best choice.
Developer status & mechanism ↗TRIUMPH-1 randomized 2,339 adults with obesity without diabetes to retatrutide or placebo for 80 weeks. In its treatment-regimen analysis, the highest-dose group averaged 25.0% weight reduction versus 3.9% with placebo. Gastrointestinal adverse events were most common.
This was a comparison with placebo, not Ozempic or tirzepatide. It does not establish a universal “best for weight loss” choice. Different analyses can produce different estimates; the guide explains the trial headlines and their limits.
Read the peer-reviewed Phase 3 trial abstract ↗ · Explore the retatrutide guide →
“GLP-3” is informal shorthand, not a recognized scientific class. Retatrutide is described scientifically as a triple receptor agonist. A higher number in an informal name is not evidence that a compound is better.
Read the developer’s explanation ↗These are educational comparisons of medicines and studied compounds. They do not establish that a GreysProtocol retail item is equivalent to a prescription medicine or the material used in a trial. FDA context ↗
Primary sources checked October 31, 2026. Retatrutide status can change; consult the linked source for updates.
▶ Watch & exploreClinical metabolic research
Understand the triple-receptor concept, separate Phase 2 from Phase 3 and read the 28.3% trial headline with its population, comparison and analysis.
EXPLORE THE TOPIC
Explore hormone physiology and distinguish biological mechanisms from measured outcomes.
▶ Watch & exploreHormone physiology
Read original human research on growth hormone, lean body mass, strength, collagen, sleep and safety. Compare what studies found, who participated, and what remains uncertain.
EXPLORE THE TOPIC
Read the tissue and nerve research questions, with personal accounts separated from study findings.
Research overviewPeptide chemistry
Trace the 4,000-gene claim to its lab data and compare what GHK-Cu studies measured in skin cells, animal wounds and human topical trials.
▶ Watch & exploreNerve research
Watch the ARA-290 episode, explore the illustrated guide and follow the studies behind the nerve-fiber research. Personal testimony is identified separately from clinical evidence.
EXPLORE THE TOPIC
Start with copper-peptide chemistry and what cell-culture studies can tell us.
Research overviewPeptide chemistry
Trace the 4,000-gene claim to its lab data and compare what GHK-Cu studies measured in skin cells, animal wounds and human topical trials.
EXPLORE THE TOPIC
Explore mitochondrial signals and the difference between laboratory findings and exercise measurements.
▶ Watch & exploreCellular signaling
Start with mitochondrial DNA and cellular energy signaling, then separate mouse intervention findings from human exercise measurements.
EXPLORE THE TOPIC
Explore brain-cell and peripheral-nerve questions, with the evidence type made clear.
▶ Watch & explorePreclinical neuroscience
Explore cell-stress experiments, learning studies in rats and a laboratory model of neuronal aging—with the limits of each finding made clear.
▶ Watch & exploreNerve research
Watch the ARA-290 episode, explore the illustrated guide and follow the studies behind the nerve-fiber research. Personal testimony is identified separately from clinical evidence.
HOW THESE GUIDES ARE PREPARED
See how sources are selected, how laboratory, animal and human evidence are separated, how videos are checked against their guides, and why widespread real-world use is not the same as a clinical study.
READ WITH CONTEXT
Explore the illustrated guide to cells, animal models and human studies ↗
Cells, animals and people provide different evidence. A finding in one model does not automatically apply to another.
A biological marker, a physical measurement and an improvement in symptoms are different outcomes.
Read the comparison, study size and follow-up alongside the finding. An explanation of a mechanism is not a treatment recommendation.